Pacira BioSciences, Inc. $PCRX Shares Purchased by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 87.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 435,143 shares of the company’s stock after acquiring an additional 202,773 shares during the period. Assenagon Asset Management S.A. owned about 1.01% of Pacira BioSciences worth $11,262,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Roxbury Financial LLC acquired a new stake in Pacira BioSciences in the fourth quarter valued at approximately $161,000. Tudor Investment Corp ET AL purchased a new stake in Pacira BioSciences during the 3rd quarter worth $480,000. CANADA LIFE ASSURANCE Co lifted its holdings in Pacira BioSciences by 10.6% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 40,903 shares of the company’s stock worth $1,035,000 after buying an additional 3,935 shares in the last quarter. Qube Research & Technologies Ltd purchased a new position in Pacira BioSciences in the third quarter valued at about $420,000. Finally, Prelude Capital Management LLC boosted its holdings in Pacira BioSciences by 50.8% in the third quarter. Prelude Capital Management LLC now owns 36,535 shares of the company’s stock valued at $942,000 after purchasing an additional 12,300 shares during the last quarter. Institutional investors and hedge funds own 99.73% of the company’s stock.

Insiders Place Their Bets

In other Pacira BioSciences news, insider Jonathan Slonin sold 3,261 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $22.82, for a total transaction of $74,416.02. Following the completion of the sale, the insider directly owned 223,640 shares of the company’s stock, valued at approximately $5,103,464.80. This represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $20.81, for a total transaction of $83,240.00. Following the completion of the transaction, the senior vice president directly owned 52,313 shares in the company, valued at approximately $1,088,633.53. This trade represents a 7.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,677 shares of company stock worth $191,980 over the last ninety days. 6.40% of the stock is owned by insiders.

Pacira BioSciences Price Performance

Shares of Pacira BioSciences stock opened at $22.88 on Friday. Pacira BioSciences, Inc. has a 52 week low of $18.80 and a 52 week high of $27.64. The company has a current ratio of 4.54, a quick ratio of 3.28 and a debt-to-equity ratio of 0.54. The stock has a market cap of $926.41 million, a PE ratio of 152.53 and a beta of 0.21. The company’s 50-day moving average price is $21.88 and its two-hundred day moving average price is $23.39.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.28). The business had revenue of $196.87 million during the quarter, compared to analyst estimates of $201.93 million. Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.91 EPS. As a group, sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.41 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on PCRX. Zacks Research cut Pacira BioSciences from a “hold” rating to a “strong sell” rating in a research note on Monday, March 9th. Wall Street Zen lowered shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Barclays cut their target price on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price objective on shares of Pacira BioSciences in a report on Friday, January 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 target price on shares of Pacira BioSciences in a report on Friday, January 9th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $30.25.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.